NASDAQ
235.99USD
-54.07 (-18.64%)
We have scored 44 news catalysts on Illumina, Inc. (ILMN) over the past 12 months. The biggest single-day move next to one of them came Aug 22, 2026, when ILMN closed +2.9%: “Illumina, Inc. Post Earnings: Buy On A Pullback”. Coverage across the window leans positive (average ticker sentiment +0.43). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
35.6B
P/E
—
EPS
—
Beta
1.42
52W range
106.12-309.35
Day range
231.18–256.06
Open
250.02
Prev close
290.06
Volume
5.4M
Avg volume
2.5M
Dividend
0.00
IPO
2000-07-28
Analysts publish price targets on ILMN, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
12 analyst price targets from $160 to $260
as of 2026-09-24
The market is 23% above the median target — more optimistic than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Illumina, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Illumina, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ILMN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
The price sits at the 92nd percentile of published models, 23% above the median target of $208, meaning the market has firmly rejected the bear cases and is already paying for a growth acceleration that most analysts have not yet endorsed.
What the disagreement turns on
Can Illumina's core sequencing segment actually deliver the +15.8% revenue growth the price requires, and is the available unit-volume data precise enough to confirm or deny that acceleration?
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $255 on 2026-09-24 — the quote has since moved -8%, so read this as a record of what was priced in then, not now.
